A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report
S. Kim(Moffitt Cancer Center), Andrew S. Brohl(Moffitt Cancer Center), Jane L. Messina(Moffitt Cancer Center), Zeynep Eroglu(Moffitt Cancer Center), Kenneth Y. Tsai(Moffitt Cancer Center), Evan Wuthrick(Moffitt Cancer Center), Joseph Markowitz(University of South Florida), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Dukagjin Blakaj(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Trevor Rose(Moffitt Cancer Center), J.J. Caudell(Moffitt Cancer Center), Jeffery S. Russell(University of Utah), Masahiko Aoki(Moffitt Cancer Center), Harsh Shah(University of Utah), L.B. Harrison(Moffitt Cancer Center), D.-T. Chen(Moffitt Cancer Center)
Cited by 5
Related Papers
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
|JAMA Oncology|2015|656
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
|Cancer|2016|375
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
|Cell Reports|2018|366
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
|The Lancet Oncology|2014|263